Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1101. Cost-efficacy of endoscopic ultrasonography with fine-needle aspiration vs. mediastinotomy in patients with lung cancer and suspected mediastinal adenopathy

Cost-efficacy of endoscopic ultrasonography with fine-needle aspiration vs. mediastinotomy in patients with lung cancer and suspected mediastinal adenopathy Cost-efficacy of endoscopic ultrasonography with fine-needle aspiration vs. mediastinotomy in patients with lung cancer and suspected mediastinal adenopathy Cost-efficacy of endoscopic ultrasonography with fine-needle aspiration vs. mediastinotomy in patients with lung cancer and suspected mediastinal adenopathy Aabakken L, Silvestri G (...) of non-small cell lung cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with verified non-small cell lung cancer and pathologically enlarged mediastinal lymph nodes. Mediastinal lymph nodes were defined as nodes of more than 10 mm short axis measurement, as detected by a CT scan. Patients with at least one enlarged station 5, 6 or 7 node underwent either EUS or MED as their next stage of treatment

NHS Economic Evaluation Database.1999

1102. Radon and lung cancer: a cost-effectiveness analysis

Radon and lung cancer: a cost-effectiveness analysis Radon and lung cancer: a cost-effectiveness analysis Radon and lung cancer: a cost-effectiveness analysis Ford E S, Kelly A E, Teutsch S M, Thacker S B, Garbe P L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) between 0.558 (best estimate) and 1 (full compliance). The probability of mitigating varied between 0.22 (best estimate) and 1 (full compliance). The probability of a post-mitigation radon test greater than 4 pCi/L was 0.05. Measure of benefits used in the economic analysis The number of lung cancer deaths prevented and number of life years were used as the primary measures of benefit. Deaths from lung cancer were discounted at an annual rate of 4%. Direct costs Direct costs were discounted

NHS Economic Evaluation Database.1999

1103. Follow-up in lung cancer: how often and for what purpose?

Follow-up in lung cancer: how often and for what purpose? Follow-up in lung cancer: how often and for what purpose? Follow-up in lung cancer: how often and for what purpose? Younes R N, Gross J L, Deheinzelin D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Two different approaches to the follow-up of patients who had undergone complete resection of non-small-cell lung cancer (NSCLC) were studied. The approaches were strict versus symptom follow-up. Strict follow-up comprised frequent visits, imaging and laboratory examinations (physical examinations, chest radiographs, CT scans and liver function tests). Symptom follow-up comprised less frequent visits (3 or less consultations per year) that were scheduled on the basis

NHS Economic Evaluation Database.1999

1104. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. 9920950 1999 02 02 1999 02 02 2013 11 21 0028-4793 340 4 1999 Jan 28 The New England journal of medicine N. Engl. J. Med. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. 265-71 For small-cell lung cancer confined to one hemithorax (limited small-cell lung (...) cancer), thoracic radiotherapy improves survival, but the best ways of integrating chemotherapy and thoracic radiotherapy remain unsettled. Twice-daily accelerated thoracic radiotherapy has potential advantages over once-daily radiotherapy. We studied 417 patients with limited small-cell lung cancer. All the patients received four 21-day cycles of cisplatin plus etoposide. We randomly assigned these patients to receive a total of 45 Gy of concurrent thoracic radiotherapy, given either twice daily

NEJM1999

1105. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer.

Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. 10102851 1999 05 06 1999 05 06 2014 06 17 0959-8138 318 7188 1999 Apr 03 BMJ (Clinical research ed.) BMJ Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. 901-4 To evaluate the effectiveness of nursing intervention for breathlessness in patients with lung cancer. Patients diagnosed with lung cancer participated (...) at baseline, 4 weeks, and 8 weeks. Nursing clinics within 6 hospital settings in the United Kingdom. 119 patients diagnosed with small cell or non-small cell lung cancer or with mesothelioma who had completed first line treatment for their disease and reported breathlessness. Visual analogue scales measuring distress due to breathlessness, breathlessness at best and worst, WHO performance status scale, hospital anxiety and depression scale, and Rotterdam symptom checklist. The intervention group improved

BMJ1999 Full Text: Link to full Text with Trip Pro

1106. Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer

Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer Goss G, Paszat L, Newman T E, Evans W K, Browman G Authors' objectives (...) To assess the use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIa non-small-cell lung cancer (NSCLC). Searching MEDLINE was searched from January 1990 to June 1997 for English-language publications using the subject headings: 'carcinoma', 'non-small cell lung', 'lung neoplasms', 'chemotherapy', 'adjuvant', 'clinical trial', 'research design' and 'practice guideline'. The search used the keywords of 'neoadjuvant', 'induction' and 'preoperative

DARE.1998

1107. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature Maintenance chemotherapy for small cell lung cancer: a critical review of the literature Maintenance chemotherapy for small cell lung cancer: a critical review of the literature Sculier J P, Berghmans T, Castaigne C, Luce S, Sotiriou C, Vermylen P, Paesmans M Authors' objectives To perform a critical review of the effectiveness of maintenance chemotherapy for small cell lung cancer (SCLC). Searching Current (...) to survival. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected for the review, or how many of the authors performed the selection. Assessment of study quality Internal validity, external validity, protocol design and analysis performance were assessed.Two quality scoring systems were applied, namely those described by Chalmers et al. (see Other Publications of Related Interest) and the European Lung Cancer Working Party (full details

DARE.1998

1108. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model

Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort (...) in the treatment of small-cell lung cancer: an analysis using a Markov model Chouaid C, Bassinet L, Fuhrman C, Monnet I, Housset B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Granulocyte colony stimulating factor (G-CSF) in the treatment

NHS Economic Evaluation Database.1998

1109. Cost-effectiveness decision analysis of mass screening for lung cancer

Cost-effectiveness decision analysis of mass screening for lung cancer Cost-effectiveness decision analysis of mass screening for lung cancer Cost-effectiveness decision analysis of mass screening for lung cancer Baba Y, Takahashi M, Tominguchi S, Kiyota S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The use of chest radiographs for screening a middle aged population for lung cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Asymptomatic male and female patients aged over 40 years old undergoing lung cancer screening in Japan. Setting Community. The economic study was carried out in Kumamoto, Japan. Dates to which data relate The effectiveness data were taken

NHS Economic Evaluation Database.1998

1110. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis

Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis Scott W J, Shepherd J, Gambhir S S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of thoracic positron emission tomography (PET) as an adjunct to thoracic CT for staging non-small cell lung cancer (NSCLC). Strategy A consisted of CT alone. The PET-based strategies considered were as follows: Strategy B implied that patients who were CT positive underwent a confirming biopsy, and if the biopsy results were negative, they proceeded to the necessary

NHS Economic Evaluation Database.1998

1111. Management of lung cancer

Management of lung cancer Management of lung cancer Management of lung cancer NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Management of lung cancer. York: Centre for Reviews and Dissemination (CRD) 1998: 12 Authors' objectives This report summarises (...) the research evidence on the management of lung cancer. Authors' conclusions Lung cancer is the third most common cause of death in the UK. The disease progresses rapidly and the prognosis is usually poor; around 80% of patients die within a year of diagnosis. Since cigarette smoking is responsible for about 90% of cases of lung cancer, action against smoking should be the primary focus of efforts to improve outcomes. A range of co-ordinated interventions to reduce smoking should be provided at both local

Health Technology Assessment (HTA) Database.1998

1112. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer

Chemotherapy in stage IV (metastatic) non-small-cell lung cancer Chemotherapy in stage IV (metastatic) non-small-cell lung cancer Chemotherapy in stage IV (metastatic) non-small-cell lung cancer Lopez P G, Stewart D J, Newman T E, Evans W K Authors' objectives To assess whether chemotherapy improves survival and quality of life in metastatic (stage IV) non-small-cell lung cancer. Searching For the original review, MEDLINE and Cancerlit were searched for material published between January 1980 (...) and June 1994. The search terms included 'non-small-cell lung cancer', 'lung neoplasms','stage IV', 'metastatic',' drug therapy', 'supportive care','clinical trials','research design','meta-analysis' and 'guidelines'. Personal files, reference lists and proceedings of meetings were also searched. The search was updated using MEDLINE (to December 2001), Cancerlit (to October 2001), the Cochrane Library (Issue 1, 2002) and proceedings of the American Society of Clinical Oncology (from 1997 to 2001

DARE.1997

1113. Use of vinorelbine in non-small-cell lung cancer

Use of vinorelbine in non-small-cell lung cancer Use of vinorelbine in non-small-cell lung cancer Use of vinorelbine in non-small-cell lung cancer Goss G D, Logan D M, Newman T E, Evans W K Authors' objectives To make recommendations about the use of vinorelbine in the management of patients with non-small-cell lung cancer (NSCLC). Searching MEDLINE searches were done for the years January 1984 to January 1994. Articles identified by the searches, articles cited in relevant papers, reviews (...) ; Vinorelbine versus vinorelbine plus cisplatin; Vinorelbine versus other single agents. Phase II studies of single agent vinorelbine in advanced NSCLC. Vinorelbine as second-line therapy in NSCLC. Participants included in the review Patients with non-small-cell lung cancer. Outcomes assessed in the review Survival is the primary end point of interest. Response and toxicity are secondary end points. How were decisions on the relevance of primary studies made? The authors do not state how the papers were

DARE.1997

1114. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection

Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection Logan D M, Lochrin C A, Darling G, Eady A, Newman T E, Evans W K Authors' objectives To assess the efficacy of postoperative adjuvant radiotherapy and chemotherapy (...) in the treatment of patients with completely resected stage II or IIIA non-small-cell lung cancer (NSCLC). Searching The authors searched the MEDLINE electronic database (1985 to June 1997) for English language publications using the keywords: 'carcinoma', 'non-small cell lung', 'resect', 'stage II', 'stage III', 'radiotherapy', 'chemotherapy', 'adjuvant', 'randomized controlled trial', 'clinical trial', 'guideline', 'research design', 'consensus' and 'recommend'. The bibliographies of review articles were

DARE.1997

1115. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer

A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer Earle C C, Evans W K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of single-agent paclitaxel (Taxol-TM) 214 mg/m^2 (3 week schedule and a median of 3 treatment cycles) in the treatment of stage IV non-small-cell lung cancer (NSCLC). Type of intervention Treatment and supportive care. Economic study type Cost-effectiveness analysis. Study population Patients suffering from stage IV non-small-cell lung cancer

NHS Economic Evaluation Database.1997

1116. The importance of sputum cytology in the diagnosis of lung cancer: a cost-effectiveness analysis

The importance of sputum cytology in the diagnosis of lung cancer: a cost-effectiveness analysis The importance of sputum cytology in the diagnosis of lung cancer: a cost-effectiveness analysis The importance of sputum cytology in the diagnosis of lung cancer: a cost-effectiveness analysis Raab S S, Hornberger J, Raffin T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) for selected patients with peripheral lesions; in particular, in patients whose probability of cancer is more than 50%. The authors found that the lower cost and better survival, especially in patients with central lesions, remained stable to variation in other reference-case assumptions. Authors' conclusions The authors concluded that for patients who undergo diagnostic evaluation of suspected lung cancer (particularly those patients presenting with centrally located lung lesions) the addition of sputa

NHS Economic Evaluation Database.1997

1117. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the population health model lung cancer module

Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the population health model lung cancer module Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the population health model lung cancer module Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the population health model lung cancer module Evans W K Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Gemcitabine (2', 2'-difluorodeoxycytidine) in non-small cell lung cancer (NSCLC). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with advanced (stage IV) non-small cell lung cancer (NSCLC

NHS Economic Evaluation Database.1997

1118. Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan

Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan Kubota K, Yamada S, Fukuda H, Tanida T, Saitou Y, Takahashi J, Yamada K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology F-fluorodeoxyglucose Position Emission Tomography (FDG-PET) and chest Computerised Axial Tomography (CT) for the differential diagnosis of cancer. FDG-PET and brain Magnetic Resonance Imaging (MRI), abdominal CT and bone scan for staging of lung cancer. Type of intervention Diagnosis. Economic

NHS Economic Evaluation Database.1997

1119. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.

Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. 9010146 1997 02 06 1997 02 06 2015 11 19 0028-4793 336 6 1997 Feb 06 The New England journal of medicine N. Engl. J. Med. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. 404-9 Polyethylene glycol (PEG)-conjugated recombinant (...) human megakaryocyte growth and development factor (MGDF, also known as PEG-rHuMGDF), a recombinant molecule related to thrombopoietin, specifically stimulates megakaryopoiesis and platelet production and reduces the severity of thrombocytopenia in animals receiving myelosuppressive chemotherapy. We conducted a randomized, double-blind, placebo-controlled dose-escalation study of MGDF in 53 patients with lung cancer who were treated with carboplatin and paclitaxel. The patients were randomly assigned

NEJM1997

1120. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. 9250182 1997 09 04 1997 09 04 2015 06 16 0140-6736 350 9072 1997 Jul 19 Lancet (London, England) Lancet Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. 161-5 Human tumour cells (...) , Middlesex, UK. Dische S S Barrett A A Harvey A A Gibson D D Parmar M M eng Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't England Lancet 2985213R 0140-6736 AIM IM Lancet. 1997 Jul 19;350(9072):156-7 9250176 Lancet. 1997 Sep 20;350(9081):888 9310628 Adult Aged Carcinoma, Non-Small-Cell Lung mortality pathology radiotherapy Dose-Response Relationship, Radiation Female Humans Lung Neoplasms mortality pathology radiotherapy

Lancet1997